Matthew Herper on Muck Rack

Matthew Herper

Verified
New York
Senior Editor — Forbes
As seen in: Forbes

Forbes reporter covering science and medicine

The Consumer Rip-Off At The Heart Of The EpiPen Scandal

forbes.com — Here's another rip-off about EpiPen that nobody's talking about: that there is a free market around drug prices, and many patients are being excluded from it. One of the terrifying things about the branded drug market is that competition often doesn't result in lower prices, especially when it comes to a [...]

Mad About Epipen? Here Are Some Ideas To Actually Fix America's Drug Pricing Mess

forbes.com — Mylan Pharmaceuticals has been raising the price of the EpiPen for six years. The world has been outraged about it for six days. Here, then, are some thoughts on turning the rage into change. "The reason people are upset by it is because it's upsetting," says David Maris, an analyst at [...]

Stealthy Biotech Revives Stalled Parkinson's Drug, Reveals Plans In Alzheimer's and ALS

forbes.com — Denali CEO Ryan Watts Denali Therapeutics, the stealthy South San Francisco biotech startup that raised $217 million last year to fight Alzheimer's, Parkinson's, and ALS, is finally lifting the curtain on its plans this morning. It is also announcing that it has raised another $130 million from investors in a private [...]

With $14 Billion Purchase, Pfizer Signals That Cancer Drug Prices Will Remain High

forbes.com — Ian Read, Chairman and Chief Executive of US drugs giant Pfizer (BEN STANSALL/AFP/Getty Images) Pfizer says it will purchase biotechnology upstart Medivation for $14 billion in cash. The main prize in the deal: Medivation's prostate cancer drug, Xtandi, which costs $120,000 a year and generated $2.2 billion in sales over its [...]

Bristol-Myers Squibb's Defeat Is A Victory For Personalized Medicine

forbes.com — Yesterday, shares of drug giant Bristol-Myers Squibb fell 16% after its breakthrough cancer drug, Opdivo, failed to slow tumor growth in previously untreated patients with non-small cell lung cancer. The news shocked Wall Street in part because in June, Merck had announced that its very similar (possibly identical) drug, Keytruda, had [...]

We Took A Bold Risk To Try To Help All Patients

forbes.com — This morning, Bristol-Myers Squibb shocked Wall Street and the world of cancer medicine with the news that its drug Opdivo had failed to show a benefit as a first choice of treatment in non-small cell lung cancer. Investor forecasts had shown Bristol getting billions of dollars in sales for this [...]

New Risks For Genentech Drug

forbes.com — Yesterday, Genentech and partner OSI Pharmaceuticals soared on news that their experimental cancer drug, Tarceva, had extended survival in late-stage lung cancer patients. OSI shares doubled, and Genentech added another $8 billion to its already large (and pricey) market value.

Theranos Live Blog

forbes.com — Elizabeth Holmes is personally presenting data about a new machine developed by her embattled blood testing startup, Theranos here at the annual meeting of the American Association for Clinical Chemistry. For my early thoughts on the presentation, read this. I'll be live-blogging the presentation until my laptop battery [...]

Theranos Presents Data On New Blood Test Machine, Remains Mum On Previous Technology

forbes.com — Theranos , the embattled blood testing startup that once claimed it could do hundreds of tests with a single drop of blood, is presenting new details about its tests here at the annual scientific meeting of the American Association for Clinical Chemistry. The presentation, which Theranos allowed Forbes to review ahead [...]

Mission Impossible Burger: Tasting The Fake Meat That Wants To Save The World

forbes.com — It bleeds, it leads. When celebrity chef David Chang announced that he would be serving the Impossible Burger-a veggie-based burger with veggie-based blood--at his restaurant in Chelsea, I had to try it. Seven years ago, I wrote a short Forbes Magazine profile of the Impossible Burger's creator, renowned biologist Pat Brown, just [...]
More Articles →
Aug 30, 2016

@ZacharyBrennan but my response to you is that Mylan is as much worried about losing share as losing price... I should maybe do that too.

Aug 30, 2016

@ZacharyBrennan yes, and the authorized generic may make being the first generic less appealing!

Aug 30, 2016

@ZacharyBrennan If the generic comes in 15% below, it might get 60% share. So company sales fall by 70%! Consumers save 15%.

Aug 30, 2016

@ZacharyBrennan but it hurts sales disproportionately to price cut...

Aug 30, 2016

@ZacharyBrennan Generic competition is actually different from branded. It brings down prices...

Aug 30, 2016

@matt_chandler @abbynach oh, no argument there. althought Auvi-Q did have a problem...

Aug 30, 2016

@TGrantBelgard @forbeshealth How do you do that? My solution would be to not try to limit starting prices, but to limit increases somehow.

Aug 30, 2016

@TGrantBelgard @forbeshealth In an ideal world, we'd leave high prices for new innovative drugs but not allow freeloaders to partake.


Are You a Journalist?

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Create a Portfolio